Protective and reversal effects of conserved dopamine neurotrophic factor on PC12 cells following 6-hydroxydopamine administration

Mei,Jiaming; Niu,Chaoshi

doi:10.3892/mmr.2015.3388

Protective and reversal effects of conserved dopamine neurotrophic factor on PC12 cells following 6-hydroxydopamine administration

Authors:
- Jiaming Mei
- Chaoshi Niu
View Affiliations

Affiliations: Department of Neurosurgery, Anhui Provincial Hospital Affiliated to Anhui Medical University, Anhui Province Key Laboratory of Brain Function and Brain Disease, Hefei, Anhui 230001, P.R. China
Published online on: February 24, 2015 https://doi.org/10.3892/mmr.2015.3388
Pages: 297-302

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Conserved dopamine neurotrophic factor (CDNF), a member of the mammalian mesencephalic astrocyte-derived neurotrophic factor family of conserved secreted factors, has been reported to protect and rescue dopaminergic neurons in vivo. PC12 pheochromocytoma cells are widely used as a cell model for Parkinson's disease (PD) for experimental studies. In the present study, PC12 cells were induced using 6‑hydroxydopamine (6‑OHDA) to mimic PD, which was used to investigate the protective and reversal effects of CDNF against PD in vitro. Cell growth was assessed using an MTT assay, the rate of cell apoptosis was detected using flow cytometry and the apoptotic morphology of cells was observed using terminal deoxynucleotidyl transferase‑mediated deoxyuridine triphosphate nick end labeling (TUNEL) staining. Pre-treatment of PC12 cells with CDNF (50, 100 and 200 nM) prior to exposure to 100 µM 6‑OHDA for 24 h, resulted in a significant increase in cell viability compared with that of 6‑OHDA only‑treated cells, with cell survival rates of 46.6, 54.7 and 69.6%, respectively. In addition, PC12 cells were treated with CDNF (50, 100 and 200 nM) following 6‑OHDA administration, which resulted in cell survival rates of 47.7, 57.6 and 57.5%, respectively. Flow cytometric and TUNEL staining analyses revealed that CDNF exhibited significant dose‑dependent protective and reversal effects on the apoptotic rate of PC12 cells following 6‑OHDA treatment. In conclusion, the results of the present study showed that CDNF exhibited neuroprotective and reversal effects on the 6‑OHDA‑induced apoptosis of PC12 cells in a dose‑dependent manner.

View Figures

View References

1	Han B, Hu J, Shen J, Gao Y, Lu Y and Wang T: Neuroprotective effect of hydroxysafflor yellow A on 6-hydroxydopamine-induced Parkinson’s disease in rats. Eur J Pharmacol. 714:83–88. 2013. View Article : Google Scholar : PubMed/NCBI
2	Airavaara M, Harvey BK, Voutilainen MH, et al: CDNF protects the nigrostriatal dopamine system and promotes recovery after MPTP treatment in mice. Cell Transplant. 21:1213–1223. 2012. View Article : Google Scholar
3	Chaturvedi RK and Flint Beal M: Mitochondrial diseases of the brain. Free Radic Biol Med. 63:1–29. 2013. View Article : Google Scholar : PubMed/NCBI
4	Lopert P, Day BJ and Patel M: Thioredoxin reductase deficiency potentiates oxidative stress, mitochondrial dysfunction and cell death in dopaminergic cells. PLoS One. 7:e506832012. View Article : Google Scholar : PubMed/NCBI
5	Cantu D, Fulton RE, Drechsel DA and Patel M: Mitochondrial aconitase knockdown attenuates paraquat-induced dopaminergic cell death via decreased cellular metabolism and release of iron and H₂O₂. J Neurochem. 118:79–92. 2011. View Article : Google Scholar : PubMed/NCBI
6	Calabrese V, Lodi R, Tonon C, et al: Oxidative stress, mitochondrial dysfunction and cellular stress response in Friedreich’s ataxia. J Neurol Sci. 233:145–162. 2005. View Article : Google Scholar : PubMed/NCBI
7	Prinz A, Selesnew LM, Liss B, Roeper J and Carlsson T: Increased excitability in serotonin neurons in the dorsal raphe nucleus in the 6-OHDA mouse model of Parkinson’s disease. Exp Neurol. 248:236–245. 2013. View Article : Google Scholar : PubMed/NCBI
8	Sadan O, Bahat-Stromza M, Barhum Y, et al: Protective effects of neurotrophic factor-secreting cells in a 6-OHDA rat model of Parkinson disease. Stem Cells Dev. 18:1179–1190. 2009. View Article : Google Scholar : PubMed/NCBI
9	Olds ME, Jacques DB and Kpoyov O: Behavioral/neurophysiological investigation of effects of combining a quinolinic acid entopeduncular lesion with a fetal mesencephalic tissue transplant in striatum of the 6-OHDA hemilesioned rat. Synapse. 49:1–11. 2003. View Article : Google Scholar : PubMed/NCBI
10	Offen D, Sherki Y, Melamed E, Fridkin M, Brenneman DE and Gozes I: Vasoactive intestinal peptide (VIP) prevents neurotoxicity in neuronal cultures: relevance to neuroprotection in Parkinson’s disease. Brain Res. 854:257–262. 2000. View Article : Google Scholar : PubMed/NCBI
11	Wang LZ, Sun WC and Zhu XZ: Ethyl pyruvate protects PC12 cells from dopamine-induced apoptosis. Eur J Pharmacol. 508:57–68. 2005. View Article : Google Scholar : PubMed/NCBI
12	Chagkutip J, Govitrapong P, Klongpanichpak S and Ebadi M: Mechanism of 1-methyl-4-phenylpyridinium-induced dopamine release from PC12 cells. Neurochem Res. 30:633–639. 2005. View Article : Google Scholar : PubMed/NCBI
13	Lindholm P, Voutilainen MH, Laurén J, et al: Novel neurotrophic factor CDNF protects and rescues midbrain dopamine neurons in vivo. Nature. 448:73–77. 2007. View Article : Google Scholar : PubMed/NCBI
14	Voutilainen MH, Bäck S, Peränen J, et al: Chronic infusion of CDNF prevents 6-OHDA-induced deficits in a rat model of Parkinson’s disease. Exp Neurol. 228:99–108. 2011. View Article : Google Scholar
15	Bäck S, Peränen J, Galli E, et al: Gene therapy with AAV2-CDNF provides functional benefits in a rat model of Parkinson’s disease. Brain Behav. 3:75–88. 2013. View Article : Google Scholar
16	Ren X, Zhang T, Gong X, Hu G, Ding W and Wang X: AAV2-mediated striatum delivery of human CDNF prevents the deterioration of midbrain dopamine neurons in a 6-hydroxy-dopamine induced parkinsonian rat model. Exp Neurol. 248:148–156. 2013. View Article : Google Scholar : PubMed/NCBI
17	Gorman AM, Szegezdi E, Quigney DJ and Samali A: Hsp27 inhibits 6-hydroxydopamine-induced cytochrome c release and apoptosis in PC12 cells. Biochem Biophys Res Commun. 327:801–810. 2005. View Article : Google Scholar : PubMed/NCBI
18	Stahl K, Mylonakou MN, Skare Ø, Amiry-Moghaddam M and Torp R: Cytoprotective effects of growth factors: BDNF more potent than GDNF in an organotypic culture model of Parkinson’s disease. Brain Res. 1378:105–118. 2011. View Article : Google Scholar : PubMed/NCBI
19	Gyárfás T, Knuuttila J, Lindholm P, Rantamäki T and Castrén E: Regulation of brain-derived neurotrophic factor (BDNF) and cerebral dopamine neurotrophic factor (CDNF) by anti-parkin-sonian drug therapy in vivo. Cell Mol Neurobiol. 30:361–368. 2010. View Article : Google Scholar
20	Gill SS, Patel NK, Hotton GR, O’Sullivan K, et al: Direct brain infusion of glial cell line-derived neurotrophic factor in parkinson disease. Nat Med. 9:589–595. 2003. View Article : Google Scholar : PubMed/NCBI
21	Patel NK, Bunnage M, Plaha P, Svendsen CN, Heywood P and Gill SS: Intraputamenal infusion of glia cell line-derived neurotrophic factor in PD: a two-year outcome study. Ann Neurol. 57:298–302. 2005. View Article : Google Scholar : PubMed/NCBI
22	Lang AE, Gill S, Patel NK, et al: Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Ann Neurol. 59:459–466. 2006. View Article : Google Scholar : PubMed/NCBI
23	Black YD, Xiao D, Pellegrino D, Kachroo A, Brownell AL and Schwarzschild MA: Protective effect of metabotropic glutamate mGluR5 receptor elimination in a 6-hydroxydopamine model of Parkinson’s disease. Neurosci Lett. 486:161–165. 2010. View Article : Google Scholar : PubMed/NCBI
24	Winner B, Desplats P, Hagl C, et al: Dopamine receptor activation promotes adult neurogenesis in an acute Parkinson model. Exp Neurol. 219:543–552. 2009. View Article : Google Scholar : PubMed/NCBI
25	Kwon IH, Choi HS, Shin KS, et al: Effects of berberine on 6-hydroxydopamine-induced neurotoxicity in PC12 cells and a rat model of Parkinson’s disease. Neurosci Lett. 486:29–33. 2010. View Article : Google Scholar : PubMed/NCBI
26	Kim Y, Li E and Park S: Insulin-like growth factor-1 inhibits 6-hydroxydopamine-mediated endoplasmic reticulum stress-induced apoptosis via regulation of heme oxygenase-1 and Nrf2 expression in PC12 cells. Int J Neurosci. 122:641–649. 2012. View Article : Google Scholar : PubMed/NCBI
27	Li X, Peng C, Li L, Ming M, Yang D and Le W: Glial cell-derived neurotrophic factor protects against proteasome inhibition-induced dopamine neuron degeneration by suppression of endoplasmic reticulum stress and caspase-3 activation. J Gerontol A Biol Sci Med Sci. 62:943–950. 2007. View Article : Google Scholar : PubMed/NCBI